An Educational Review About Using Cost Data for the Purpose of Cost-Effectiveness Analysis.
Journal
PharmacoEconomics
ISSN: 1179-2027
Titre abrégé: Pharmacoeconomics
Pays: New Zealand
ID NLM: 9212404
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
pubmed:
13
2
2019
medline:
28
4
2020
entrez:
13
2
2019
Statut:
ppublish
Résumé
This paper provides an educational review covering the consideration of costs for cost-effectiveness analysis (CEA), summarising relevant methods and research from the published literature. Cost data are typically generated by applying appropriate unit costs to healthcare resource-use data for patients. Trial-based evaluations and decision analytic modelling represent the two main vehicles for CEA. The costs to consider will depend on the perspective taken, with conflicting recommendations ranging from focusing solely on healthcare to the broader 'societal' perspective. Alternative sources of resource-use are available, including medical records and forms completed by researchers or patients. Different methods are available for the statistical analysis of cost data, although consideration needs to be given to the appropriate methods, given cost data are typically non-normal with a mass point at zero and a long right-hand tail. The choice of covariates for inclusion in econometric models also needs careful consideration, focusing on those that are influential and that will improve balance and precision. Where data are missing, it is important to consider the type of missingness and then apply appropriate analytical methods, such as imputation. Uncertainty around costs should also be reflected to allow for consideration on the impacts of the CEA results on decision uncertainty. Costs should be discounted to account for differential timing, and are typically inflated to a common cost year. The choice of methods and sources of information used when accounting for cost information within CEA will have an effect on the subsequent cost-effectiveness results and how information is presented to decision makers. It is important that the most appropriate methods are used as overlooking the complicated nature of cost data could lead to inaccurate information being given to decision makers.
Identifiants
pubmed: 30746613
doi: 10.1007/s40273-019-00771-y
pii: 10.1007/s40273-019-00771-y
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Pagination
631-643Subventions
Organisme : Department of Health
Pays : United Kingdom
Références
Value Health. 2012 Jul-Aug;15(5):650-5
pubmed: 22867773
Value Health. 2010 Dec;13(8):867-72
pubmed: 20946187
Pharmacoeconomics. 2017 Dec;35(Suppl 1):11-19
pubmed: 29052162
Value Health. 2017 Apr;20(4):699-704
pubmed: 28408014
Pharmacoeconomics. 2017 May;35(5):561-573
pubmed: 28110382
Clinicoecon Outcomes Res. 2012;4:145-55
pubmed: 22719214
Pharmacoeconomics. 2005;23(12):1229-42
pubmed: 16336017
Stat Methods Med Res. 2013 Jun;22(3):278-95
pubmed: 21220355
Health Econ. 2011 Aug;20(8):897-916
pubmed: 20799344
Appl Health Econ Health Policy. 2013 Jun;11(3):155-61
pubmed: 23529715
Alzheimers Dement. 2013 Jul;9(4):429-435.e17
pubmed: 23142433
Health Econ. 2004 Dec;13(12):1203-10
pubmed: 15386669
Soc Sci Med. 2019 Jan;220:353-361
pubmed: 30513485
Psychooncology. 2016 Jan;25(1):77-83
pubmed: 26087260
Value Health. 2018 Jun;21(6):640-649
pubmed: 29909868
Pharmacoeconomics. 2017 Dec;35(Suppl 1):5-6
pubmed: 29052155
PLoS One. 2015 Dec 18;10(12):e0140662
pubmed: 26684872
Health Technol Assess. 2014 Feb;18(9):1-224
pubmed: 24524660
Stat Med. 2011 Feb 20;30(4):377-99
pubmed: 21225900
Pharmacoeconomics. 2019 Feb;37(2):119-130
pubmed: 30474803
Health Econ. 2006 Jul;15(7):677-87
pubmed: 16491461
Health Econ. 2016 Aug;25(8):933-8
pubmed: 27374115
Health Econ. 2007 May;16(5):531-6
pubmed: 17001749
Med Decis Making. 2012 Jan-Feb;32(1):209-20
pubmed: 21610256
BMC Med Res Methodol. 2019 Jan 9;19(1):8
pubmed: 30626337
BMJ Open. 2012 Nov 19;2(6):
pubmed: 23166129
Health Care Anal. 2012 Sep;20(3):297-318
pubmed: 21909720
Pharmacoeconomics. 2019 Jan;37(1):1-6
pubmed: 30187294
Lung Cancer. 2012 Jun;76(3):472-7
pubmed: 22226627
Med Decis Making. 2012 Sep-Oct;32(5):690-700
pubmed: 22990084
Pharmacoeconomics. 2018 Jul;36(7):745-758
pubmed: 29779120
Pharmacoeconomics. 2010;28(12):1079-96
pubmed: 21080734
Age Ageing. 2014 Sep;43(5):703-7
pubmed: 25059421
J Health Econ. 2001 Jul;20(4):461-94
pubmed: 11469231
Health Econ. 2011 Feb;20(2):212-24
pubmed: 20091763
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
Arch Dis Child. 2005 Aug;90(8):840-4
pubmed: 16040885
J Health Serv Res Policy. 2004 Oct;9(4):197-204
pubmed: 15509405
J Health Econ. 1999 Jun;18(3):341-64
pubmed: 10537899
Soc Sci Med. 2018 Mar;200:59-64
pubmed: 29421472
Pharmacoeconomics. 2016 Feb;34(2):155-60
pubmed: 26645571
J R Stat Soc Ser A Stat Soc. 2016 Oct;179(4):951-974
pubmed: 27773970
Med Care. 1989 Mar;27(3 Suppl):S217-32
pubmed: 2646490
Stat Med. 2016 Jul 30;35(17):2907-20
pubmed: 26893215
PLoS One. 2015 Jun 29;10(6):e0131949
pubmed: 26121465
Value Health. 2010 Jun;13 Suppl 1:S22-5
pubmed: 20618791
Value Health. 2012 Sep-Oct;15(6):828-34
pubmed: 22999132
Health Econ. 2003 May;12(5):377-92
pubmed: 12720255
Health Econ. 2005 May;14(5):487-96
pubmed: 15497198
Pharmacoeconomics. 2008;26(9):799-806
pubmed: 18767899
Med Decis Making. 2012 Sep-Oct;32(5):667-77
pubmed: 22990082
Pharmacoeconomics. 2009;27(6):519-28
pubmed: 19640014
PLoS One. 2018 Jan 2;13(1):e0190283
pubmed: 29293611
Pharmacoeconomics. 2015 Apr;33(4):355-66
pubmed: 25595871
Med Decis Making. 2012 Sep-Oct;32(5):722-32
pubmed: 22990087
Med Decis Making. 2012 Sep-Oct;32(5):701-11
pubmed: 22990085
Value Health. 2009 Jun;12(4):409-18
pubmed: 19900249
Health Technol Assess. 2012;16(46):1-323
pubmed: 23177626
Health Econ. 2012 Oct;21(10):1201-16
pubmed: 21905152
Health Technol Assess. 2004 Sep;8(36):iii-iv, ix-xi, 1-158
pubmed: 15361314
Value Health. 2013 Mar-Apr;16(2):231-50
pubmed: 23538175
Eur Heart J Qual Care Clin Outcomes. 2016 Jan 20;2(2):125-140
pubmed: 27042338
Health Econ. 2015 Sep;24(9):1192-212
pubmed: 25929525
Health Technol Assess. 2015 Feb;19(14):1-503, v-vi
pubmed: 25692211
Health Econ. 1994 Mar-Apr;3(2):95-104
pubmed: 8044216
J Health Econ. 2008 May;27(3):531-43
pubmed: 18192044
J Health Econ. 1999 Apr;18(2):153-71
pubmed: 10346351
Inj Prev. 2016 Feb;22(1):59-67
pubmed: 26136460
Health Econ. 2004 May;13(5):461-75
pubmed: 15127426
Health Econ. 2011 Jan;20(1):2-15
pubmed: 21154521
Pharmacoeconomics. 2013 Oct;31(10):863-76
pubmed: 23979963
Value Health. 2012 May;15(3):570-9
pubmed: 22583469
Pharmacoeconomics. 2017 Dec;35(Suppl 1):33-41
pubmed: 29052164
Biostatistics. 2005 Jan;6(1):93-109
pubmed: 15618530
Annu Rev Public Health. 2018 Apr 1;39:489-505
pubmed: 29328879
Health Technol Assess. 1999;3(2):1-134
pubmed: 10448202
J Natl Cancer Inst. 2010 Mar 3;102(5):298-306
pubmed: 20160168
J Clin Epidemiol. 2016 Jun;74:93-106.e2
pubmed: 26845747
Med Decis Making. 2013 Aug;33(6):743-54
pubmed: 23341049
PLoS One. 2015 May 05;10(5):e0121340
pubmed: 25942421
Stat Med. 2005 Jan 15;24(1):131-45
pubmed: 15515137
Stat Med. 1999 Aug 15;18(15):1903-42
pubmed: 10440877
BMJ. 2013 May 20;346:f2350
pubmed: 23692896
Pharmacoeconomics. 2017 Dec;35(Suppl 1):21-31
pubmed: 29052157
Pharmacoeconomics. 2016 Feb;34(2):161-8
pubmed: 26386702
Health Econ. 2018 Jun;27(6):1024-1040
pubmed: 29573044